Skip to main content

Table 3 Total savings from patent expiration during 2020–2024 for various scenarios

From: Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility

Scenario Budget savings Changes from base case savings
Korea (₩): million US ($): million % of expendituresa Korea (₩): million US ($): million (%)
Base case ₩234,429 $203 20%    
Based on group B cancer drugs ₩157,633 $136 14% - ₩76,795 -$66 −33%
Based on group C cancer drugs ₩434,523 $376 38% ₩200,095 $173 + 85%
Generic entrance: 6 months delay ₩165,904 $144 14% - ₩68,524 -$59 −29%
Risk-sharing scheme rebate of 25% ₩221,465 $192 19% -₩12,963 -$11 −6%
Adjustment for reimbursement ₩210,985 $183 18% - ₩23,443 -$20 −10%
Growth of off-patent market ₩255,316 $221 22% ₩20,888 $18 + 9%
Price level of originators ₩206,929 $179 18% -₩27,499 -$24 −12%
Price levels of generics/biosimilars ₩234,771 $203 20% ₩343 $0 0%
New pricing policy (July 2020) ₩246,082 $213 21% ₩11,654 $10 + 5%
  1. a The proportion of budget savings was calculated by dividing budget savings for each scenario by the 5-year total expenditure for the base case (₩1,145,470 million)
\